Data analytics firm Palantir (PLTR) is the top-performing stock in the benchmark S&P 500 index so far this year.
Pliant (PLRX) stock plunged 61% on news it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with ...
We recently compiled a list of the 13 Best Natural Gas and Oil Dividend Stocks To Buy. In this article, we are going to take a look at where BP p.l.c.
Needham analyst Joseph Stringer lowered the firm’s price target on Pliant Therapeutics (PLRX) to $10 from $38 and keeps a Buy rating on the ...
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed ...
Palantir's Q4 earnings beat expectations, with revenue up 36% YoY and EPS up 75% YoY. Check out why I remain bearish on PLTR ...
The result has been tremendous growth. Just four years ago, Palantir had 14 U.S. commercial customers. Today, that number has ...
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.